retatrutide trial results october 2025 Retatrutide: The Triple Agonist That's Redrawing the Map of Obesity Medicine October 27, 2025: U.K. regulators

Establish an evening routine and try to stick to it

Clin Endocrinol (Oxf) 2016;84(6):851-7

For a POTS patient, simply changing posture can result in a skyrocketing heart rate, palpitations, tremors, and a profound sense of panic or anxietyoften referred to in the patient community as an "adrenaline dump." The body is trapped in a perpetual state of hyper-arousal, which is incredibly draining and contributes significantly to the profound fatigue seen in these conditions

September 5th, 2025: Research Suggests GLP-1 Medications May Raise Kidney Cancer Risk Amid Growing Litigation A new study published in JAMA Oncology suggests that GLP-1 receptor agonists such as Ozempic and Mounjaro could increase the risk of kidney cancer, despite appearing to lower the risk of certain other cancers